- Home
- FMAO vs GLUE Comparison
FMAO vs GLUE Comparison
Compare FMAO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- GLUE
- Stock Information
- Founded
- FMAO 1897
- GLUE 2019
- Country
- FMAO United States
- GLUE United States
- Employees
- FMAO N/A
- GLUE N/A
- Industry
- FMAO Savings Institutions
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- GLUE Health Care
- Exchange
- FMAO Nasdaq
- GLUE Nasdaq
- Market Cap
- FMAO 344.8M
- GLUE 356.3M
- IPO Year
- FMAO N/A
- GLUE 2021
- Fundamental
- Price
- FMAO $27.28
- GLUE $5.69
- Analyst Decision
- FMAO Hold
- GLUE Buy
- Analyst Count
- FMAO 2
- GLUE 3
- Target Price
- FMAO $26.00
- GLUE $12.67
- AVG Volume (30 Days)
- FMAO 22.4K
- GLUE 1.2M
- Earning Date
- FMAO 02-11-2025
- GLUE 03-13-2025
- Dividend Yield
- FMAO 3.23%
- GLUE N/A
- EPS Growth
- FMAO N/A
- GLUE N/A
- EPS
- FMAO 1.69
- GLUE N/A
- Revenue
- FMAO $98,003,000.00
- GLUE $14,975,000.00
- Revenue This Year
- FMAO N/A
- GLUE N/A
- Revenue Next Year
- FMAO $8.11
- GLUE N/A
- P/E Ratio
- FMAO $16.17
- GLUE N/A
- Revenue Growth
- FMAO N/A
- GLUE N/A
- 52 Week Low
- FMAO $18.99
- GLUE $3.21
- 52 Week High
- FMAO $34.15
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- FMAO 43.10
- GLUE 35.93
- Support Level
- FMAO $25.67
- GLUE $5.51
- Resistance Level
- FMAO $27.87
- GLUE $6.38
- Average True Range (ATR)
- FMAO 1.26
- GLUE 0.48
- MACD
- FMAO 0.01
- GLUE -0.05
- Stochastic Oscillator
- FMAO 49.71
- GLUE 14.90
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.